|
Wednesday 7th October 2026 |
Text too small? |
CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30 September 2026. Continued progress in customer contracting and the development of CDC’s capacity pipeline was offset by the macroeconomic impact of a material increase in the forward yield curve, resulting in higher assumed interest costs over the forecast period.
The valuation decreased by A$78 million from 30 June 2026 to A$18.45 billion, reflecting the mid-point of the assessed valuation range of A$17.4 billion to A$19.6 billion. Infratil’s 49.69% interest in CDC is valued at A$9,168 million, down A$45 million from A$9,213 million at 30 June 2026, which reflected Infratil’s interest of 49.72%.
Further valuation details are included in the attached presentation document.
Enquiries should be directed to:
Brett Jackson
Investor Relations
Email: brett.jackson@infratil.com
Authorised for release by:
Matthew Ross
Infratil Chief Financial Officer
No comments yet
IPL - Interim Results HY27
SEK - Seeka Announces Launch of 2026 Grower Loyalty Share Scheme
SAN - Sanford delivers a record profit for FY26
November 17th Morning Report
MPG - Metro Performance Glass Limited- Receipt of Takeover Notice
SKO - Serko FY27 Half Year Results Announcement
TRU - TruScreen Receives Product Registration in Kenya
TEM - Transaction in Own Shares
AIA - October 2026 Monthly traffic update
PFI - Q1 FY27 Dividend and Leasing Update